Latest Growth Strategy News

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Chrysos Corporation Limited reported a robust 1H FY26 with revenue up 49% and EBITDA soaring 152%, driven by expanding adoption of its PhotonAssay technology and strategic global deployments.

Magellan Financial Group reported a 27% drop in statutory net profit but maintained stable operating profit and increased earnings per share by 5%, supported by ongoing share buybacks. The company declared a fully franked interim dividend up 50%, reflecting confidence despite investment performance challenges.

SHAPE Australia Corporation Limited has reported a robust first half of FY26, with significant gains in revenue, profits, and project pipeline, underpinned by strategic sector diversification and a key acquisition.

SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.

Australian Finance Group Ltd (AFG) has reported a record-breaking half-year profit for HY26, driven by strong broker network growth and improved funding terms that reduce cash rate sensitivity.

Australian Bond Exchange Holdings has completed a $982,071 private placement, attracting new international and domestic investors to support its growth strategy.

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Baby Bunting has reported record half-year sales and margin growth for 1H FY26, underpinned by its Store of the Future refurbishments and strategic expansions. The company maintains its full-year profit guidance while unveiling a new exclusive partnership with premium brand Stokke.

Smart Parking Limited has reported record first-half results for FY26, driven by strong organic growth and a successful US acquisition that boosted earnings per share by over 30%.